Pharmaceuticals

US FDA CDER and CBER guidance of interest

By 2022-10-31T14:40:00

AdobeStock_175310323

The US Food and Drug Administration (FDA) has been steadily increasing the number of guidance documents produced on a yearly basis over the past decade. However, even with this increased pace, there are numerous topics that industry is looking to the FDA for clarity, especially newer topics like gene therapy, ...

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

 

Not a TOPRA member yet? Join our global community.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Become a member today!

Have you heard what you’re missing? Listen now to the RegRapPod podcast show, for free!